Zealand Pharma A/S
CSE:ZEAL

Watchlist Manager
Zealand Pharma A/S Logo
Zealand Pharma A/S
CSE:ZEAL
Watchlist
Price: 494 DKK 4.29% Market Closed
Market Cap: 35.3B DKK

Wall Street
Price Targets

ZEAL Price Targets Summary
Zealand Pharma A/S

Wall Street analysts forecast ZEAL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ZEAL is 805.23 DKK with a low forecast of 434.3 DKK and a high forecast of 1 176 DKK.

Lowest
Price Target
434.3 DKK
12% Downside
Average
Price Target
805.23 DKK
63% Upside
Highest
Price Target
1 176 DKK
138% Upside
Zealand Pharma A/S Competitors:
Price Targets
OXB
Oxford BioMedica PLC
22% Upside
GBIO
Generation Bio Co
393% Upside
000403
Pacific Shuanglin Bio pharmacy Co Ltd
31% Upside
CRSP
CRISPR Therapeutics AG
58% Upside
2171
CARsgen Therapeutics Holdings Ltd
33% Upside
GYRE
Gyre Therapeutics Inc
120% Upside
603392
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
2% Downside
4584
Kidswell Bio Corporation
80% Upside

Revenue
Forecast

Revenue Estimate
Zealand Pharma A/S

For the last 13 years the compound annual growth rate for Zealand Pharma A/S's revenue is -6%. The projected CAGR for the next 3 years is 284%.

-6%
Past Growth
284%
Estimated Growth
Estimates Accuracy
-12%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Zealand Pharma A/S

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Net Income
Forecast

Net Income Estimate
Zealand Pharma A/S

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-45%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ZEAL's stock price target?
Price Target
805.23 DKK

According to Wall Street analysts, the average 1-year price target for ZEAL is 805.23 DKK with a low forecast of 434.3 DKK and a high forecast of 1 176 DKK.

What is Zealand Pharma A/S's Revenue forecast?
Projected CAGR
284%

For the last 13 years the compound annual growth rate for Zealand Pharma A/S's revenue is -6%. The projected CAGR for the next 3 years is 284%.

Back to Top